Apr 30, 2024, 19:43
Erman Akkus: Our new study Prostate Cancer and PARPi
Erman Akkus, Medicine Oncology and Internal Medicine Specialist at Ankara University, shared on X:
“Our new study has been published!
Coskun Yazgan, Emre Yekedüz, Yüksel Ürün.
Prostate Cancer and PARPi: Thromboembolic Risk
Increased risk of thrombosis with PARPi compared to controls: 4.3% vs. 2.2%, OR:1.98, 95% CI: 1.06-3.70, P=0.030
Should be considered when deciding prophylaxis in patients with prostate cancer treated with PARPi.
Thanks a lot to Yüksel Ürün and Emre Yekedüz for their support and mentoring. What a great chance to be in the same department!”
Source: Erman Akkus/X
OncoDaily
cancer
Cancer research
cancer treatment
cancer treatment side effects
Coskun Yazgan
Emre Yekedüz
Erman Akkus
healthcare news
Medical News
Medical Publication
Medical Research
Medical Research Paper
Medical Study
Medical Study Findings
Medical Study Results
OncoDaily
Oncology
oncology research
PARP inhibitors
PARPi
prostate cancer
Prostate cancer treatment
Research
research findings
Thromboembolic Risk
Thrombosis Prevention
Thrombosis Risk
Yüksel Ürün
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14